The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1449
Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an oral liquid formulation of glycerol phenylbutyrate (Ravicti – Hyperion) for chronic management of patients ≥2 years old with urea cycle disorders that cannot be adequately managed by a protein- restricted diet. Sodium phenylbutyrate (Buphenyl, and generics), another oral drug approved by the FDA for this indication, has a bitter taste. The new product, which contains no sodium, has little or no taste. Either drug must be used in addition to a protein-restricted diet and, if needed, dietary supplementation with amino acids and other nutrients.

UREA CYCLE DISORDERS — Deficiencies in the enzymes that convert nitrogen from ammonia into urea are the cause of urea cycle disorders, which can present at birth. Accumulation of ammonia can lead to neurologic toxicity ranging from mild cognitive impairment to cerebral edema, seizures, coma, and death. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders
Article code: 1449c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian